---
layout: default
title: Omalizumab
description: "Omalizumab çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚é«˜è­‰æ“šç­‰ç´š L2ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 117
evidence_level: L1
indication_count: 10
---

# Omalizumab

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L2</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Omalizumabï¼šå¾ éæ•æ€§æ°£å–˜ åˆ° æ”¯æ°£ç®¡ç‚èˆ‡ç•°ä½æ€§çš®è†šç‚

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Omalizumab å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Omalizumabï¼ˆå–œç‘æ¨‚ï¼‰æ˜¯ä¸€ç¨®æŠ— IgE å–®æ ªæŠ—é«”ï¼Œç”¨æ–¼æ²»ç™‚é‡åº¦éæ•æ€§æ°£å–˜å’Œæ…¢æ€§è•éº»ç–¹ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå°**æ”¯æ°£ç®¡ç‚ (bronchitis)** å’Œ**ç•°ä½æ€§çš®è†šç‚ (atopic eczema)** æœ‰æ½›åœ¨æ²»ç™‚æ•ˆæœï¼Œç›®å‰æœ‰å¤šé …è‡¨åºŠè©¦é©—å’Œæ–‡ç»æ”¯æŒé€™äº›é æ¸¬ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | é‡åº¦éæ•æ€§æ°£å–˜ã€æ…¢æ€§é¼»ç«‡ç‚ä½µé¼»æ¯è‚‰ã€æ…¢æ€§è‡ªç™¼æ€§è•éº»ç–¹ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | bronchitisã€atopic eczemaã€obstructive lung diseaseã€allergic asthmaã€çš®è†šç‚ã€intrinsic asthmaã€bronchial neoplasm (disease)ã€acne keloidã€acrodermatitis chronica atrophicansã€hydroa vacciniforme, familial |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.99% (æ”¯æ°£ç®¡ç‚), 99.97% (ç•°ä½æ€§çš®è†šç‚) |
| è­‰æ“šç­‰ç´š | L2 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 2 å¼µ |
| å»ºè­°æ±ºç­– | Explore |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. bronchitis</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">100.00%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p><p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ"></p>
<p>Omalizumab é€šéèˆ‡æ¸¸é›¢ IgE çµåˆï¼Œé˜»æ­¢ IgE èˆ‡è‚¥å¤§ç´°èƒå’Œå—œé¹¼æ€§çƒä¸Šçš„é«˜è¦ªå’ŒåŠ›å—é«”ï¼ˆFcÎµRIï¼‰çµåˆï¼Œå¾è€ŒæŠ‘åˆ¶éæ•æ€§ç‚ç—‡åæ‡‰ã€‚</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<p><strong>æ”¯æ°£ç®¡ç‚ç›¸é—œè©¦é©—ï¼š</strong></p>

<table>
<thead>
<tr>
<th>è©¦é©—ç·¨è™Ÿ</th>
<th>éšæ®µ</th>
<th>ç‹€æ…‹</th>
<th>ä¸»è¦ç ”ç©¶ç›®æ¨™</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02049294</td>
<td>Phase 2/3</td>
<td>å®Œæˆ</td>
<td>å—œé…¸æ€§çƒæ€§æ”¯æ°£ç®¡ç‚æ‚£è€…çš„é¡å›ºé†‡æ¸›é‡æ•ˆæœ</td>
</tr>
</tbody>
</table>

<p><strong>ç•°ä½æ€§çš®è†šç‚ç›¸é—œè©¦é©—ï¼š</strong></p>

<table>
<thead>
<tr>
<th>è©¦é©—ç·¨è™Ÿ</th>
<th>éšæ®µ</th>
<th>ç‹€æ…‹</th>
<th>ä¸»è¦ç ”ç©¶ç›®æ¨™</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT02300701</td>
<td>Phase 4</td>
<td>å®Œæˆ</td>
<td>è©•ä¼° omalizumab å°åš´é‡å°å…’ç•°ä½æ€§æ¿•ç–¹çš„ç™‚æ•ˆ</td>
</tr>
<tr>
<td>NCT01179529</td>
<td>Phase 2</td>
<td>å®Œæˆ</td>
<td>è©•ä¼° omalizumab åœ¨æˆäººä¸­é‡åº¦ AD çš„æ²»ç™‚æ½›åŠ›</td>
</tr>
<tr>
<td>NCT00822783</td>
<td>Phase 4</td>
<td>å®Œæˆ</td>
<td>è©•ä¼°æŠ— IgE å°ç•°ä½æ€§çš®è†šç‚æ¨¹çªç´°èƒçš„å½±éŸ¿</td>
</tr>
<tr>
<td>NCT01678092</td>
<td>Phase 1</td>
<td>å®Œæˆ</td>
<td>Omalizumab åœ¨ç•°ä½æ€§çš®è†šç‚æ‚£è€…çš„å–®ä¸­å¿ƒç ”ç©¶</td>
</tr>
</tbody>
</table>

<p>å¤šé …è©¦é©—æ¢ç´¢äº† omalizumab åœ¨ç•°ä½æ€§çš®è†šç‚ä¸­çš„æ‡‰ç”¨ï¼Œçµæœè¡¨æ˜éƒ¨åˆ†æ‚£è€…å¯èƒ½å—ç›Šã€‚</p>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr>
<th>PMID</th>
<th>å¹´ä»½</th>
<th>é¡å‹</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/16222080/">16222080</a></td>
<td>2005</td>
<td>Review</td>
<td>Omalizumab æ ¸å‡†åŠä¸Šå¸‚å¾Œç¶“é©—ï¼ŒåŒ…æ‹¬å°æ”¯æ°£ç®¡ç‚çš„è¨è«–</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/30196731/">30196731</a></td>
<td>2018</td>
<td>Review</td>
<td>Omalizumab åœ¨å¸è¸ç›¸é—œæ°£é“ç–¾ç—…ï¼ˆåŒ…æ‹¬æ…¢æ€§æ”¯æ°£ç®¡ç‚ï¼‰ç®¡ç†ä¸­çš„æŒ‘æˆ°</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/35369622/">35369622</a></td>
<td>2022</td>
<td>Journal Article</td>
<td>Omalizumab ç”¨æ–¼ä¸­è€å¹´åš´é‡éæ•æ€§æ°£å–˜-COPD é‡ç–Š</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. atopic eczema</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ18 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04037176" target="_blank">NCT04037176</a></td><td>PHASE4</td><td>COMPLETED</td><td>20</td><td>Treatment With Omalizumab in Food Allergic Children (TOFAC)</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05564221" target="_blank">NCT05564221</a></td><td>PHASE1</td><td>COMPLETED</td><td>46</td><td>A Randomized, Double-Blind, Placebo/Active Controlled, Multiple Ascending Dose, ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04060550" target="_blank">NCT04060550</a></td><td>N/A</td><td>UNKNOWN</td><td>36</td><td>Investigate the Impact of Increased IgE on Innate Anti-herpes Simplex Virus 1 Re...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05674695" target="_blank">NCT05674695</a></td><td>N/A</td><td>RECRUITING</td><td>2500</td><td>Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis The...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01179529" target="_blank">NCT01179529</a></td><td>PHASE2</td><td>COMPLETED</td><td>N/A</td><td>Single- Arm Trial to Identify Potential Markers Underlying Variability in Respon...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 13 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35980214/" target="_blank">35980214</a></td><td>2022</td><td>Article</td><td>Journal of the Europ</td><td>European guideline (EuroGuiDerm) on atopic eczema: part I - ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36878860/" target="_blank">36878860</a></td><td>2023</td><td>Article</td><td>International forum </td><td>International consensus statement on allergy and rhinology: ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36411004/" target="_blank">36411004</a></td><td>2023</td><td>Article</td><td>Immunology and aller</td><td>Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Ast...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39600395/" target="_blank">39600395</a></td><td>2024</td><td>Article</td><td>Allergologie select</td><td>Biologics in allergology and clinical immunology: Update on ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38812522/" target="_blank">38812522</a></td><td>2024</td><td>Article</td><td>Frontiers in immunol</td><td>Effectiveness and safety of systemic therapy for moderate-to...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. obstructive lung disease</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ50 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00624832" target="_blank">NCT00624832</a></td><td>PHASE4</td><td>COMPLETED</td><td>60</td><td>A Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00286416" target="_blank">NCT00286416</a></td><td>NA</td><td>UNKNOWN</td><td>60</td><td>Double Blind Study to Determine Effect of Omalizumab Treatment in Patients With ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00870584" target="_blank">NCT00870584</a></td><td>PHASE4</td><td>COMPLETED</td><td>271</td><td>A 26-week Randomized, Double-blind, Placebo-controlled, Multi-center Study to Ev...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04998604" target="_blank">NCT04998604</a></td><td>PHASE4</td><td>COMPLETED</td><td>360</td><td>A Randomized, Double-blind, Head-to-head Comparison of Dupilumab Versus Omalizum...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01584687" target="_blank">NCT01584687</a></td><td>PHASE4</td><td>UNKNOWN</td><td>6</td><td>mRNA Expression as a Biomarker of Xolair (Omalizumab) Response</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 45 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36740144/" target="_blank">36740144</a></td><td>2023</td><td>Article</td><td>The Journal of aller</td><td>Comparative effectiveness of omalizumab, mepolizumab, and du...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37869947/" target="_blank">37869947</a></td><td>2023</td><td>Article</td><td>European review for </td><td>Biologics in allergic rhinitis.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36581073/" target="_blank">36581073</a></td><td>2023</td><td>Article</td><td>The journal of aller</td><td>Omalizumab in Allergic Bronchopulmonary Aspergillosis: A Sys...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39186985/" target="_blank">39186985</a></td><td>2024</td><td>Article</td><td>The Journal of aller</td><td>Comparative effectiveness of dupilumab and omalizumab on ast...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41033334/" target="_blank">41033334</a></td><td>2025</td><td>Article</td><td>The Lancet. Respirat</td><td>Dupilumab versus omalizumab in patients with chronic rhinosi...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. dermatitis</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.97%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ19 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04037176" target="_blank">NCT04037176</a></td><td>PHASE4</td><td>COMPLETED</td><td>20</td><td>Treatment With Omalizumab in Food Allergic Children (TOFAC)</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05564221" target="_blank">NCT05564221</a></td><td>PHASE1</td><td>COMPLETED</td><td>46</td><td>A Randomized, Double-Blind, Placebo/Active Controlled, Multiple Ascending Dose, ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04060550" target="_blank">NCT04060550</a></td><td>N/A</td><td>UNKNOWN</td><td>36</td><td>Investigate the Impact of Increased IgE on Innate Anti-herpes Simplex Virus 1 Re...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05674695" target="_blank">NCT05674695</a></td><td>N/A</td><td>RECRUITING</td><td>2500</td><td>Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis The...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01179529" target="_blank">NCT01179529</a></td><td>PHASE2</td><td>COMPLETED</td><td>N/A</td><td>Single- Arm Trial to Identify Potential Markers Underlying Variability in Respon...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 14 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/30717578/" target="_blank">30717578</a></td><td>2019</td><td>Article</td><td>Giornale italiano di</td><td>Omalizumab for atopic dermatitis: evidence for and against i...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/27337170/" target="_blank">27337170</a></td><td>2017</td><td>Article</td><td>International journa</td><td>Omalizumab for atopic dermatitis: case series and a systemat...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36878860/" target="_blank">36878860</a></td><td>2023</td><td>Article</td><td>International forum </td><td>International consensus statement on allergy and rhinology: ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36411004/" target="_blank">36411004</a></td><td>2023</td><td>Article</td><td>Immunology and aller</td><td>Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Ast...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35980214/" target="_blank">35980214</a></td><td>2022</td><td>Article</td><td>Journal of the Europ</td><td>European guideline (EuroGuiDerm) on atopic eczema: part I - ...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. bronchial neoplasm (disease)</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.95%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ2 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06869382" target="_blank">NCT06869382</a></td><td>PHASE4</td><td>COMPLETED</td><td>26</td><td>Comparative Analysis of ICS Combined with LABA Versus Addition of Omalizumab on ...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04680117" target="_blank">NCT04680117</a></td><td>NA</td><td>UNKNOWN</td><td>150</td><td>Defining the Severe Paediatric Asthma Endotype: an Integrated Approach Combining...</td></tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20955114/" target="_blank">20955114</a></td><td>2010</td><td>Article</td><td>Expert opinion on bi</td><td>Omalizumab for pediatric asthma.</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. acne keloid</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.94%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. acrodermatitis chronica atrophicans</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.93%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. hydroa vacciniforme, familial</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.93%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. neonatal dermatomyositis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.93%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. secondary interstitial lung disease specific to childhood associated with a connective tissue disease</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.92%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­— | å–œç‘æ¨‚å‡æ™¶æ³¨å°„åŠ‘150æ¯«å…‹ | æ³¨å°„åŠ‘ | é‡åº¦æŒçºŒéæ•æ€§æ°£å–˜ã€æ…¢æ€§é¼»ç«‡ç‚ä½µé¼»æ¯è‚‰ã€æ…¢æ€§è‡ªç™¼æ€§è•éº»ç–¹ |

## å®‰å…¨æ€§è€ƒé‡

**é‡è¦è­¦å‘Šï¼š**
- **éæ•æ€§åæ‡‰/Anaphylaxis**ï¼šç½•è¦‹ä½†å¯èƒ½è‡´å‘½ï¼Œå»ºè­°æ³¨å°„å¾Œè§€å¯Ÿ
- æ³¨å°„éƒ¨ä½åæ‡‰
- ç—…æ¯’æ„ŸæŸ“ï¼ˆä¸Šå‘¼å¸é“æ„ŸæŸ“ï¼‰
- é ­ç—›

**çµ¦è—¥é™åˆ¶ï¼š**
- éœ€æ ¹æ“šé«”é‡å’Œè¡€æ¸… IgE æ°´å¹³è¨ˆç®—åŠ‘é‡
- è¡€æ¸… IgE 30-1300 IU/mLï¼ˆæ°£å–˜é©æ‡‰ç—‡ï¼‰
- éœ€åœ¨é†«ç™‚å ´æ‰€çµ¦è—¥ä¸¦è§€å¯Ÿ

**ç•°ä½æ€§çš®è†šç‚æ³¨æ„ï¼š**
- è¨±å¤š AD æ‚£è€… IgE æ°´å¹³è¶…é 700 IU/mLï¼Œå¯èƒ½è¶…å‡ºå»ºè­°åŠ‘é‡ç¯„åœ
- è‡¨åºŠè©¦é©—çµæœä¸ä¸€è‡´


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Neoplasms** ğŸŸ¡ Moderate
- æ‡‰è¬¹æ…ä½¿ç”¨æœ¬è—¥ç‰©ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šExplore**

**ç†ç”±ï¼š**
Omalizumab å°ç•°ä½æ€§çš®è†šç‚å’Œæ”¯æ°£ç®¡ç‚çš„é æ¸¬å…·æœ‰åˆç†çš„è—¥ç†å­¸åŸºç¤ï¼Œä¸”æœ‰å¤šé …è‡¨åºŠè©¦é©—æ¢ç´¢é€™äº›æ‡‰ç”¨ã€‚ç•°ä½æ€§çš®è†šç‚çš„è©¦é©—çµæœé¡¯ç¤ºéƒ¨åˆ†æ‚£è€…å—ç›Šï¼Œä½†ç™‚æ•ˆä¸ä¸€è‡´ï¼Œå¯èƒ½èˆ‡ IgE æ°´å¹³å’Œå…¶ä»–å› ç´ æœ‰é—œã€‚æ”¯æ°£ç®¡ç‚ï¼ˆç‰¹åˆ¥æ˜¯å—œé…¸æ€§çƒæ€§æ”¯æ°£ç®¡ç‚ï¼‰èˆ‡éæ•æ€§æ°£å–˜æœ‰é‡ç–Šæ©Ÿåˆ¶ï¼Œä½¿ç”¨ omalizumab å…·æœ‰åˆç†æ€§ã€‚

ç„¶è€Œï¼Œéœ€æ³¨æ„ï¼š
- Dupilumab å·²æˆç‚ºç•°ä½æ€§çš®è†šç‚çš„æ¨™æº–ç”Ÿç‰©è£½åŠ‘æ²»ç™‚
- æ”¯æ°£ç®¡ç‚ç—…å› å¤šæ¨£ï¼Œéæ‰€æœ‰é¡å‹éƒ½é©åˆæŠ— IgE æ²»ç™‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ˜ç¢ºå“ªäº›äºç¾¤æ‚£è€…æœ€å¯èƒ½å¾ omalizumab å—ç›Š
- èˆ‡ç¾æœ‰æ¨™æº–æ²»ç™‚ï¼ˆå¦‚ dupilumab for ADï¼‰çš„æ¯”è¼ƒç ”ç©¶
- é–‹ç™¼é æ¸¬æ²»ç™‚åæ‡‰çš„ç”Ÿç‰©æ¨™è¨˜
- è©•ä¼°é«˜ IgE æ°´å¹³æ‚£è€…ï¼ˆ>700 IU/mLï¼‰çš„åŠ‘é‡ç­–ç•¥

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Hydroxyurea]({{ "/drugs/hydroxyurea/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Oteracil]({{ "/drugs/oteracil/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Isosorbide Dinitrate]({{ "/drugs/isosorbide_dinitrate/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Gemcitabine]({{ "/drugs/gemcitabine/" | relative_url }}) - è­‰æ“šç­‰ç´š L2
- [Carboplatin]({{ "/drugs/carboplatin/" | relative_url }}) - è­‰æ“šç­‰ç´š L2

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Omalizumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/omalizumab/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_omalizumab,
  title = {Omalizumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/omalizumab/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
